Resveratrol and Adipose-derived Mesenchymal Stem Cells Are Effective in the Prevention and Treatment of Doxorubicin Cardiotoxicity in Rats

REFERENCES

• Simbre VC, Duffy SA, Dadlani GH, Cardiotoxicity of cancer chemotherapy implications for children. Pediatr Drugs. 2005;7:187–202.
   PubMedGoogle Scholar
• Mertens AC. Cause of mortality in 5-year survivors of childhood cancer. Pediatr Blood Cancer. 2007;48:723–726.
   Google Scholar
• Yeh JM, Nekhlyudov L, Goldie SJ, A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010;152:409–417.
   PubMed Web of Science ®Google Scholar
• Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011;108:619–628.
   PubMed Web of Science ®Google Scholar
• Blanco JG, Sun CL, Landier W, Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the children's oncology group. J Clin Oncol. 2012;30:1415–1421.
   PubMed Web of Science ®Google Scholar
• Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab. 2009;10:530–546.
   PubMed Web of Science ®Google Scholar
• Danz ED, Skramsted J, Henry N, Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med. 2009;46:1589–1597.
   PubMed Web of Science ®Google Scholar
• Tatlıdede E, Şehirli O, Velioğlu-Övünç A, Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res. 2009;43:195–205.
   PubMed Web of Science ®Google Scholar
• Zhang C, Feng Y, Qu S, Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res. 2011;90:538–545.
   PubMed Web of Science ®Google Scholar
• Prezioso L, Tanzi S, Galaverna F, Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease? Cardiovasc Hematol Agents Med Chem. 2010;8:55–75.
   Google Scholar
• Li YM, Guo YP, Liu Y. Cancer chemotherapy induces cardiotoxicity by targeting cardiac stem cells. J Cell Mol Med. 2010;14:2630–2632.
   Google Scholar
• Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115:155–162.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20:4517–4522.
   PubMed Web of Science ®Google Scholar
• Sieswerda E, van Dalen EC, Postma A, Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2011;7:CD008011.
   Google Scholar
• Kaushal S, Jacobs JP, Gossett JG, Innovation in basic science: stem cells and their role in the treatment of paediatric cardiac failure –opportunities and challenges. Cardiol Young. 2009;19: 74–84.
   Google Scholar
• Christiansen S. Clinical management of doxorubicin-induced heart failure. J Cardiovasc Surg. 2011;52:133–138.
   Google Scholar
• Bernstein HS, Srivastava D. Stem cell therapy for cardiac disease. Pediatr Res. 2012;71:491–499.
   Google Scholar
• Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev. 2004;13:436–448.
   PubMed Web of Science ®Google Scholar
• Cowan CM, Shi YY, Aalami OO, Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat Biotechnol. 2004;22:560–567.
   PubMed Web of Science ®Google Scholar
• Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol. 2001;155;197–212.
   PubMedGoogle Scholar
• Bryja J, Konecny A. Fast sex identification in wild mammals using PCR amplification of the Sry gene. Folia Zool. 2003;52:269–274.
   Web of Science ®Google Scholar
• Ise H, Nikaido T, Negishi N, Effective hepatocyte transplantation using rat hepatocytes with low asialoglycoprotein receptor expression. Am J Pathol. 2004;165:501–510.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Markus MA, Morris BJ. Resveratrol: Cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol. 2009;41:2125–2128.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Mahmoud AM, El-Sherbiny GA, Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif. 2011;44:591–601.
   PubMed Web of Science ®Google Scholar
• Kweon SH, Song JH, Kim TS. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun. 2010;395:104–110.
   PubMed Web of Science ®Google Scholar
• Bergmann O, Bhardwaj RD, Bernard S, Evidence for cardiomyocyte renewal in humans. Science. 2009;324: 98–102.
   PubMed Web of Science ®Google Scholar
• De Angelis A, Piegari E, Cappetta D, Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276–292.
   Google Scholar
• Haynesworth SE, Baber MA, Caplan AI. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone. 1992;13:69–80.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu T, Song K, Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct. 2008;26:664–675.
   PubMed Web of Science ®Google Scholar
• Rüster B, Göttig S, Ludwig RJ, Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 2006;108:3938–3944.
   PubMed Web of Science ®Google Scholar
• Van Linthout S, Stamm C, Schultheiss HP, Tschöpe C. Mesenchymal stem cells and inflammatory cardiomyopathy: cardiac homing and beyond. Cardiol Res Pract. 2011;2011:757154.
   PubMedGoogle Scholar
• Lin YC, Leu S, Sun CK, Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. J Transl Med. 2010;8:88.
   PubMedGoogle Scholar
• Makino S, Fukuda K, Miyoshi S, Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697–705.
   PubMed Web of Science ®Google Scholar
• Qi Z, Zhang Y, Liu L, Mesenchymal stem cells derived from different origins have unique sensitivities to different chemotherapeutic agents. Cell Biol Int. 2012; Jun 14. [Epub ahead of print].
   Google Scholar
• Strauer BE, Brehm M, Schannwell CM. The therapeutic potential of stem cells in heart disease. Cell Prolif. 2008;41:126–145.
   PubMed Web of Science ®Google Scholar
• Zeinaloo AA, Zanjani KS, Bagheri MM, Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatr Transplant. 2011;15:E183–E186.
   Google Scholar
• Nagaya N, Kangawa K, Itoh T, Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005;112:1128–1135.
   PubMed Web of Science ®Google Scholar
• Nakanishi C, Yamagishi M, Yamahara K, Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun. 2008:374:11–16.
   PubMed Web of Science ®Google Scholar
• Banas A, Teratani T, Yamamoto Y, IFATS Collection: In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver Injury. Stem Cells. 2008;26:2705–2712.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li GS, Li GC, Autologous mesenchymal stem cells transplantation in adriamycin-induced cardiomyopathy. Chin Med J. 2005;118:73–76.
   Google Scholar
• Chen Y, Liu W, Li W, Autologous bone marrow mesenchymal cell transplantation improves left ventricular function in a rabbit model of dilated cardiomyopathy. Exp Mol Pathol. 2010;88:311–315.
   Google Scholar
• Di GH, Jiang S, Li FQ, Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated tissue injury in a pre-clinical mouse model. Cytotherapy. 2012;4:412–422.
   Google Scholar
• Mu Y, Cao G, Zeng Q, Li Y. Transplantation of induced bone marrow mesenchymal stem cells improves the cardiac function of rabbits with dilated cardiomyopathy via upregulation of vascular endothelial growth factor and its receptors. Exp Biol Med. 2011;236:1100–1107.
   Google Scholar
• Chiu R. Bone-marrow stem cells as a source for cell therapy. Heart Fail Rev. 2003;8:247–251.
   Google Scholar
• Singla DK, Ahmed A, Singla R, Yan B. Embryonic stem cells improve cardiac function in doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. Cell Transplant. 2012;Mar 22. [Epub ahead of print]
   Google Scholar
• Sun CK, Chang LT, Sheu JJ, Bone marrow–derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy. Crit Care Med. 2009;37:1197–1205.
   PubMed Web of Science ®Google Scholar
• Rupp S, Bauer J, Tonn T, Intracoronary administration of autologous bone marrow–derived progenitor cells in a critically ill two-yr-old-child with dilated cardiomyopathy. Pediatr Transplant. 2009:13:620–623.
   PubMed Web of Science ®Google Scholar
• Zeinaloo AA, Zanjani KS, Khosroshahi AG. Further follow up of the cardiomyopathic patient treated by intracoronary administration of autologous mesenchymal stem cells. Pediatr Transplant. 2011;15:442.
   Google Scholar
• Rivas J, Menéndez JJ, Arrieta R, Usefulness of intracoronary therapy with progenitor cells in patients with dilated cardiomyopathy: bridge or alternative to heart transplantation? An Pediatr. 2011;74:218–225.
   Google Scholar
• Olguntürk R, Kula S, Sucak GT, Peripheric stem cell transplantation in children with dilated cardiomyopathy: preliminary report of first two cases. Pediatr Transplant. 2010;14:257–260.
   Google Scholar